Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...
The Thousand Oaks, Calif.-based company reported first-quarter results on Thursday, including an update on its weight loss drug in development, which led analysts to update their Amgen stock price ...
The S&P 500 jumped 1.3% on Friday, May 3, 2024, as the latest jobs report showed a cooling labor market, revitalizing hopes for a near-term interest rate cut.
On the earnings front, the biotech beat estimates with non-GAAP EPS of $3.96 vs. the expected $3.88. Total revenue of $7.45 billion was in line with analysts' consensus expectation. Its strong revenue ...
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy ...
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The ...